ASMB

22.1901.38%
LR

Lisa R. Johnson-Pratt

Independent Director

Dr. Lisa R. Johnson-Pratt, M.D., B.S., serves as Sasineprocel Development Lead and Chief Commercial Officer at Aspen Neuroscience, Inc. since January 2026 and served as its Senior Vice President & Therapeutic Program Lead since February 2024 until November 2025 and Executive Vice President of Therapeutic Program Lead since November 2025 until 2026. She is Senior Vice President & Therapeutic Program Lead at Aspen Neuroscience, Inc. from February 2024. She joined Aspen Neuroscience, Inc. in February 2024. She guides therapeutic development for ANPD001, the first autologous neuron replacement to treat Parkinson's disease (PD) and new product strategy for Aspen. She serves as Director of Internet Sciences Inc. from December 28, 2023. She had been Senior Vice President of New Product Strategy at Ionis Pharmaceuticals, Inc. since January 2021 until October 2022. Dr. Johnson Pratt has served as Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), which is focused on discovering, developing and commercializing RNA-targeted therapeutics for a broad range of diseases Since November 2020. She serves as Independent Director of Assembly Biosciences, Inc. since May 2021. She served as Independent Director at TRACON Pharmaceuticals, Inc. since March 2021 until July 31, 2024. She served as Senior Vice President of New Product Strategy at Akcea Therapeutics, Inc. since March 2020 until Ionis’s acquisition of Akcea, which was consummated in October 2020. She led an integrated medical team responsible for the commercialization strategy of two novel late stage antisense assets. Dr. Johnson-Pratt has broad business and commercialization leadership experience. Dr. Johnson-Pratt has expertise in the pharmaceutical industry including leadership positions in marketing, operations and clinical research and development. Since November 2020, Dr. Johnson-Pratt has served as Senior Vice President of Commercial of Ionis Pharmaceuticals, Inc. Dr. Johnson-Pratt was Head of Global Pharma Commercial Operations at GSK from November 2013 to July 2019. She also served as Head of Early Pipeline Commercial Strategy supporting assets in early-stage development across multiple therapeutic areas, including oncology, from May 2015 to February 2018. Previously, Dr. Johnson-Pratt was with GlaxoSmithKline (GSK), where she served as Vice President of global franchise operations since January 2018 until July 2019. She joined GSK as Head of pipeline and oncology commercial strategy since June 2015 until July 2019 and also served as marketing Director of innovative assets at Stiefel Laboratories, a GSK company from 2013 to 2015. Prior to GSK, Dr. Johnson-Pratt worked at Merck & Co. Inc. from 2004 to 2013, holding several leadership roles including most business unit Director, Vietnam. Her career has spanned globally, including time in China and Vietnam. She is also the Founder of Ananias Ventures, LLC, which supports projects focused on issues related to vulnerable women and children. From 1996 to 2013, Dr. Johnson-Pratt held clinical development and commercial leadership roles at Merck & Co. Inc. She is on the board of directors of Young People in Recovery, a national non-profit that supports young people to thrive after recovering from substance abuse. She received both her B.S. in science and Doctor of Medicine degrees from Howard University and completed her residency in internal medicine and a fellowship in clinical pharmacology and pharmaceutical medicine at Howard University Hospital. She holds a Diploma of Pharmaceutical Medicine from the Royal College of Physicians. 09/11/2025 -197021300 09/11/2025 15364633 Null N Title HM/HD/HY TM/TD/TY W/H. She joined Aspen Neuroscience, Inc. in February 2024. She guides therapeutic development for ANPD001, the first autologous neuron replacement to treat Parkinson's disease (PD) and new product strategy for Aspen. She serves as Director of Internet Sciences Inc. from December 28, 2023. She had been Senior Vice President of New Product Strategy at Ionis Pharmaceuticals, Inc. since January 2021 until October 2022. Dr. Johnson Pratt has served as Senior Vice President, New Product Planning at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), which is focused on discovering, developing and commercializing RNA-targeted therapeutics for a broad range of diseases Since November 2020. She serves as Independent Director of Assembly Biosciences, Inc. since May 2021. She served as Independent Director at TRACON Pharmaceuticals, Inc. since March 2021 until July 31, 2024. She served as Senior Vice President of New Product Strategy at Akcea Therapeutics, Inc. since March 2020 until Ionis’s acquisition of Akcea, which was consummated in October 2020. She led an integrated medical team responsible for the commercialization strategy of two novel late stage antisense assets. Dr. Johnson-Pratt has broad business and commercialization leadership experience. Dr. Johnson-Pratt has expertise in the pharmaceutical industry including leadership positions in marketing, operations and clinical research and development. Since November 2020, Dr. Johnson-Pratt has served as Senior Vice President of Commercial of Ionis Pharmaceuticals, Inc. Dr. Johnson-Pratt was Head of Global Pharma Commercial Operations at GSK from November 2013 to July 2019. She also served as Head of Early Pipeline Commercial Strategy supporting assets in early-stage development across multiple therapeutic areas, including oncology, from May 2015 to February 2018. Previously, Dr. Johnson-Pratt was with GlaxoSmithKline (GSK), where she served as Vice President of global franchise operations since January 2018 until July 2019. She joined GSK as Head of pipeline and oncology commercial strategy since June 2015 until July 2019 and also served as marketing Director of innovative assets at Stiefel Laboratories, a GSK company from 2013 to 2015. Prior to GSK, Dr. Johnson-Pratt worked at Merck & Co. Inc. from 2004 to 2013, holding several leadership roles including most business unit Director, Vietnam. Her career has spanned globally, including time in China and Vietnam. She is also the Founder of Ananias Ventures, LLC, which supports projects focused on issues related to vulnerable women and children. From 1996 to 2013, Dr. Johnson-Pratt held clinical development and commercial leadership roles at Merck & Co. Inc. She is on the board of directors of Young People in Recovery, a national non-profit that supports young people to thrive after recovering from substance abuse. She received both her B.S. in science and Doctor of Medicine degrees from Howard University and completed her residency in internal medicine and a fellowship in clinical pharmacology and pharmaceutical medicine at Howard University Hospital. She holds a Diploma of Pharmaceutical Medicine from the Royal College of Physicians.

Positions